In response to the pandemic, companies like Arev NanoTec Brands Inc. (CSE:AREV)(OTC:AREVF) are working to identify broad spectrum antiviral agents derived from medicinal photochemistry sources including bioactive compounds sourced from Moringa oleifera and Moringa ovalifolia, which could offer a wide range of antiviral treatments against the virus.
Also known as the “drumstick tree,” Moringa reportedly has inhibitory actions against several viruses. In addition, according to Chromatography Today, researchers “found that several of the phytochemicals showed a high binding affinity with the virus and could act as virus inhibitors. The compound with the highest activity was apigenin-7-O-rutinoside and the team also found that several of the phytochemicals had antioxidant properties which would ameliorate the post-COVID secondary infection.”
In fact, its medicinal qualities could be of great importance to companies fighting the current health pandemic, like Gilead Sciences Inc. (NASDAQ:GILD), Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), and Novavax Inc. (NASDAQ:NVAX), as well.
Arev NanoTec Brands Inc. (CSE: AREV)(OTC: AREVF) is pursuing collaborations
AREV produces functional ingredients through its proprietary extraction systems and methods.
It’s applying nanotech methods to create premium ingredients for products that have an increased bioavailability. Then, it sells product to targeted natural health, medical, functional food, nutraceutical, sport nutrition markets.
Arev NanoTec Brands is utilizing its proprietary extraction technologies and facilitating initial efforts to identify broad spectrum antiviral agents derived from medicinal photochemistry sources including bioactive compounds sourced from Moringa oleifera and Moringa ovalifolia, identified in peer-reviewed publications as presenting a wide range of antiviral activity, and may demonstrate high affinity with viral protease inhibition.
In response to the CoVid19 pandemic AREV is pursuing collaborations with a number of world renowned University centers to facilitate advanced extraction of potential antiviral phytochemicals from medicinal plant libraries for screening specific small molecules that may be used to develop drugs against COVID-19 and other pandemic viral pathogens” said Mike Withrow, CEO, AREV Nanotec . “The work AREV already is doing for raw material sourcing in the natural products industry has allowed the evolution of corporate expertise to now become relevant for advancing discoveries in medicinal photochemistry”
AREV’s current efforts to secure the antiviral characteristics of COvid19’s Mpro which remains as the important drug target against COVID-19 infection, will involve grant solicitation from funding sources for pre-clinical discover include NSF’s Rapid Response Research (RAPID) program to mobilize funding for high priority projects and the NIH Consortium for Advancing Research on Botanical and Other Natural Products (CARBON) Program, working with the National Center for Complementary and Integrative Health (NCCIH) as well as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership and Biomedical Advanced Research and Development Authority (BARDA) to address the COVID-19 pandemic that are directing requests for proposals to numerous biopharmaceutical companies.
More than 2,100 plant species globally have the potential for being used as medical plants and it has been estimated, that plant derived drugs constitute as much as 25% of the total therapeutics while in fast developing countries such as India and China, the contribution is as much as 80%.
Dr Roscoe M. Moore, Jr., DVM, MPH, PhD, Frmr US Assist. Surgeon General (retired), former Epidemic Intelligence Service Officer (EIS) at the Centers for Disease Control and Prevention (CDC) and a Board member of the Global Virus Network at the Institute of Human Virology, University of Maryland Medical Center stated “this initiative with AREV Nanotechnologies to secure molecular docking studies in-silico evaluations which identify indicated drug-likeness properties towards target protein from medicinal plants for inhibitors of COVID-19 main protease (Mpro), a potential drug target are being designed and promise to afford enormous opportunity for new therapeutic discovery”
The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Arev NanoTec Brands Inc. by a third party. We own ZERO shares of Arev NanoTec Brands Inc. Please click here for full disclaimer.
Contact Information:
2818047972
[email protected]
